Heart failure with preserved ejection fraction (HFpEF), with associated pulmonary hypertension is an increasingly large medical problem. Phosphodiesterase (PDE)-5 inhibition may be of value in this population, but data are scarce and inconclusive.
Introduction
Heart failure with preserved ejection fraction (HFpEF) is an increasingly large medical and epidemiological problem, for which no evidence-based treatment is available.
1,2 A significant proportion of HFpEF patients has concomitant pulmonary hypertension, which complicates its clinical course. 3 Once sustained increased pulmonary pressures are present, these changes often result in increased right ventricular (RV) afterload and RV failure, which is associated with an even worse outcome. 4, 5 Sildenafil is a potent phosphodiesterase type 5 (PDE-5) inhibitor that increases cyclic guanosinemonophosphate (cGMP) levels causing endogenous nitric oxide-mediated vasodilatation in both systemic and pulmonary vasculature. 6 As sildenafil selectively reduces pulmonary vascular resistance (PVR) and is recognized as an effective therapy for pulmonary arterial hypertension (PAH), 6, 7 it is suggested that treatment with sildenafil decreases pulmonary artery pressures and thereby symptoms in patients with HFpEF and pulmonary hypertension. To date, only two randomized placebo-controlled trials have investigated the effects of sildenafil in patients with HFpEF. The first single centre study, including patients with HFpEF and pulmonary hypertension, demonstrated beneficial effects of sildenafil on invasively measured pulmonary haemodynamics, echocardiographic variables, and quality of life. 8 This positive study was then followed by a much larger, multi-centre non-invasive trial including both HFpEF patients with and without pulmonary hypertension. In contrast to the positive findings of the first study, treatment with sildenafil did not improve exercise capacity or symptoms. 9 These conflicting results have led to speculations that sildenafil may be only effective in selected HFpEF patients with associated pulmonary hypertension. The aim of the present randomized double-blind, placebo-controlled trial was to investigate the effects of sildenafil on invasive haemodynamic measurements and exercise capacity in patients with pulmonary hypertension due to HFpEF.
Methods

Study design
This was a single centre, prospective, randomized, and double-blind, placebo-controlled trial. An independent data safety monitoring board reviewed safety data every 6 months throughout the trial. The Trial and Coordination Center (University Medical Center Groningen, www.tcc.nl) was responsible for data management and statistical analysis. The study conforms to the Declaration of Helsinki and the Medical Research Involving Human Subjects Act. The institutional review board and local ethic committee approved the study, and all patients provided written informed consent. This trial is registered at ClinicalTrials.gov, number NCT01726049.
Objectives
The primary objective of the study was to evaluate the effect of 12-week treatment with sildenafil when compared with placebo on invasively measured mean pulmonary artery pressure (PAP) in patients with HFpEF and pulmonary hypertension. Secondary objectives were the effect of sildenafil on pulmonary artery wedge pressure (PAWP), cardiac output, and exercise capacity, measured by cardiopulmonary exercise testing.
Participants
Eligible patients were ≥18 years with symptomatic HFpEF [left ventricular ejection fraction (LVEF) ≥45% and New York Heart Association (NYHA) functional class II -IV] and pulmonary hypertension. Pulmonary hypertension was diagnosed by mean PAP .25 mmHg and mean PAWP .15 mmHg invasively measured by right-sided cardiac catheterization. 7 Key exclusion criteria included severe non-cardiac limitation to exercise, significant left-sided valve disease and other causes of pulmonary hypertension. Detailed inclusion and exclusion criteria are provided in Supplementary material online.
Randomization and study medication
Eligible patients were randomly assigned in a 1:1 ratio according to a computer-generated random sequence to one of the two treatment groups using a block size of four. Sildenafil and matching placebo were administrated orally in tablets and were provided by Pfizer Global Pharmaceuticals, were identical in appearance and were supplied to the study site in identical-masked kits.
Study procedures
The study population was recruited among patients with HFpEF with severe heart failure symptoms. At our centre, a right heart catheterization is part of clinical care policy in HFpEF patients with echocardiographic signs of pulmonary hypertension. Clinically stable patients underwent a right heart catheterization and simultaneous echocardiogram to determine LVEF performed by the same cardiologist and ultrasound technician. We screened 109 HFpEF patients with high likelihood of pulmonary hypertension. Fifty-two patients provided written informed consent (Figure 1 
Sample size calculation
In a pilot sample of eight patients with HFpEF, mean PAP was 38.0 mmHg with a standard deviation of 8.5 mmHg. With an anticipated 20% reduction in mean PAP, an a of 0.05 (two sided) and a s of 8.5, a total of 20 evaluable patients were required in each intervention group to achieve a power of 80%. We expected a dropout rate of 20%. Therefore, a total number of 52 patients had to be randomized to obtain at least 40 evaluable patients.
Statistical analyses
Efficacy analysis was performed according to the intention-to-treat (ITT) principle. In addition, treatment effect was also analysed in the per-protocol set (see Supplementary material online). Differences in change from baseline between groups were evaluated using a Student t-test for normally distributed data, and Mann-Whitney U-test for nonnormally distributed data. Treatment effects are presented using point estimates and 95% CIs. For the quantitative primary and secondary endpoints data at Week 12, one-way analysis of variance was applied on the change from baseline. In case of missing data at Week 12, a substitution/imputation approach was considered for the primary and secondary efficacy endpoints. In this, the nature of missing data was taken into consideration (e.g. due to clinical event, death, or missing completely at random). The substitution/imputation approach was determined prior to unblinding during the determination of the study analysis sets. All statistical analyses were performed using SAS w for Windows TM , version 9.3 and SPSS, version 22.
Results
Baseline characteristics
Between October 2011 and September 2014, 52 patients with HFpEF and pulmonary hypertension were randomized to receive sildenafil or placebo (Figure 1) . Baseline characteristics are summarized in Table 1 . We observed some imbalances between the two treatment arms based on standardized differences, as can be expected in small studies (see Supplementary material online, Table S1 ). The proportion of patients with a pre-capillary component of pulmonary hypertension is summarized in Table 2 . Using the definitions transpulmonary gradient (TPG) .12 mmHg, diastolic pulmonary gradient (DPG) ≥7 mmHg and PVR .240 dynes/s/cm 25 , 52, 12, and 35%, respectively, of patients had a pre-capillary component of pulmonary hypertension. In these subgroups, median TPG was 18 (15 -20) mmHg, median DPG was 9 (9 -13) mmHg, and median PVR was 321 (269-387) dynes/s/cm 25 ( Table 2) .
Primarily, 13 patients could not be taken into account in the efficacy analysis ( Figure 1) . One patient died due to heart failure, and was considered as a potential 'treatment failure'. Prior unblinding, missing data of this patient were imputed with the highest increase for the variable of interest. 
Effects of sildenafil in HFpEF with pulmonary hypertension
Study outcomes
After 12 weeks of therapy, mean change in PAP from baseline to Week 12 was 22.4 (95% CI 24.5 to 20.3) mmHg in the sildenafil group, whereas change in mean change in PAP from baseline to Week 12 was 24.7 (95% CI 27.1 to 22.3) mmHg in the placebo group (P ¼ 0.14, Figure 2 , Table 3 ). The mean PAP trajectories of each individual patient are visualized in Supplementary material online, Figure S2 . In the subgroup .240 dynes/s/cm 25 , treatment ef- Table 3 ). The Pearson's correlation between left ventricular end-diastolic pressure and PAWP was 0.848 (P , 0.001).
In the sildenafil group, mean change in cardiac output from baseline to Week 12 was 20.4 (95% CI 20.9 to 0.1) L/min. In the placebo group, mean change in cardiac output from baseline to Week 12 was 20.2 (95% CI 20.5 to 0.1) L/min (P ¼ 0.37, Table 3 ). Table 4 summarizes haemodynamic data of the cardiac catheterization at baseline and 12 weeks. In the sildenafil group, mean change in peak VO 2 from baseline to Week 12 was 0.2 (95% CI 20.9 to 1.4) mL/min/kg. In the placebo group, mean change in peak VO 2 from baseline to Week 12 was 0.7 (95% CI 20.3 to 1.6) mL/min/ kg (P ¼ 0.51, 
Safety analysis
During follow-up, one patient receiving sildenafil died due to heart failure (4%), and one patient receiving placebo died due to intestinal ischaemia (4%). Adverse events occurred in 22 patients (85%) who received sildenafil and 21 (81%) patients who received placebo (P ¼ 1.00). Prevalence of known adverse effects of sildenafil, such as headache, dyspepsia, (orthostatic) hypotension, increased erection and respiratory tract infection, was higher in the sildenafil group. No major NYHA reclassifications were observed during follow-up ( Figure 3) . Detailed adverse events are listed in Supplementary material online, Table S4 .
Discussion
The present single centre, randomized double-blind, and placebocontrolled trial shows that sildenafil does not reduce pulmonary artery pressures in patients with HFpEF with predominantly isolated post-capillary pulmonary hypertension. In addition, treatment with sildenafil does not favourably affect other invasive haemodynamics or exercise capacity. Our data therefore do not support the use of sildenafil in these patients.
Sildenafil is a potent inhibitor of PDE-5 that is widely used and proven to be effective in the treatment of PAH and recommended in current European Society of Cardiology Guidelines on pulmonary hypertension. 7 In addition, sildenafil is also used in a significant proportion of patients with heart failure and associated pulmonary hypertension, although data to support this use are limited. So far there are only two clinical studies with sildenafil that have been conducted in patients with HFpEF and they yielded contradictory results. 8, 9 Our findings are in line with the largest study conducted in this field so far. This clinical study by Redfield et al. studied the effect of sildenafil in 216 symptomatic HFpEF patients (NYHA class II -IV, LVEF ≥50%) on exercise capacity and symptoms, compared with placebo. 9 In this trial, evidence for pulmonary hypertension was not an inclusion criterion, although the actual median pulmonary arterial systolic pressure was 41 (33 -51) mmHg. After 24 weeks, treatment with sildenafil (60 mg t.i.d) did not improve exercise capacity or symptoms compared with placebo. 9 The second, smaller study by Guazzi et al. studied the effect of sildenafil (50 mg t.i.d.) in 44 HFpEF patients with an LVEF ≥50% and systolic PAP ≥40 mmHg, estimated by ultrasound, who were recruited among patients with high blood pressure, new onset of dyspnoea and limited physical capacity. 8 After 12 months of treatment, a decrease in invasively measured pulmonary haemodynamics, echocardiographic variables, and quality of life was observed. 8 One important difference between these previous studies is that Guazzi and colleagues included only patients with pulmonary hypertension, while Redfield and colleagues included patients with and without pulmonary hypertension. In the present study, only HFpEF patients with invasively proven pulmonary hypertension were included and the diagnosis of HFpEF was meticulously established. One explanation for the seemingly contradictory findings with the study of Guazzi et al. may be related to the differences in characteristics of the study populations. The patients enrolled in our study are in line with the typical patient with HFpEF, i.e. usually elderly, female patient, and with a history of hypertension and atrial fibrillation. 10 The patients that were enrolled in the study of in response to study by Guazzi et al., 8 Forfia and Borlaug already pointed out that the patient profile of the study of Guazzi et al. was not typical for HFpEF patients with pulmonary hypertension based on the presence of profound RV systolic dysfunction and RV failure. 11 Furthermore, patients of the Guazzi study had higher systemic blood pressures, higher right atrial pressure, and higher PVR. To date, two types of pulmonary hypertension due to left-sided heart disease have been recognized: isolated post-capillary pulmonary hypertension, and combined post-capillary and pre-capillary pulmonary hypertension. 12 In current guidelines, the pre-capillary component of pulmonary hypertension is defined by a TPG (mean PAP-PAWP) of .12 mmHg. 7 However, recent recommendations suggest that the pre-capillary component is better reflected by DPG (diastolic PAP -PAWP) .7 mmHg, since DPG is less dependent on cardiac output, but this definition has its limitations as well. 12, 13 Probably, an elevated PVR is the most reliable marker of pulmonary vasculopathy. In the study of For the quantitative primary and secondary endpoints data at Week 12, one-way analysis of variance was applied on the change from baseline. Differences in change from baseline between groups were evaluated using a Student's t-test. PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure.
PVR was .240 dynes (.3 woodunits). 8 In our study population, 52, 35, and 12% had a TPG .12 mmHg, PVR .240 dynes/s/cm 25 , and DPG ≥7 mmHg, respectively. In addition, only moderately elevated TPG, PVR and DPG were noted in these subgroups and in the overall study population, median TPG, PVR, and DPG were not above these cut-off values. These findings indicate that we included both HFpEF patients with isolated post-capillary pulmonary hypertension, and HFpEF patients with combined post-and pre-capillary pulmonary hypertension with a mild-to-moderate pre-capillary component. We found no evidence that sildenafil had an effect in the PVR .240 dynes/s/cm 25 subgroup. It should be stressed however that the numbers within the subgroups were too small to draw conclusions. It thus remains to be evaluated whether there is a role for sildenafil in selected patients with HFpEF with a significant precapillary component of pulmonary hypertension. However, this interesting subgroup may be overestimated, since in a HFpEF population that is characterized by several comorbidities, the aetiology of pulmonary hypertension is often multi-factorial. Effects of sildenafil in HFpEF with pulmonary hypertension
Our findings suggest that the described group of patients with HFpEF and associated pulmonary hypertension do not benefit from treatment with sildenafil. These findings are in contrast with the results that were seen in patients with PAH. This may be explained by the different pathophysiologies of pulmonary hypertension due to left heart failure and PAH. In HFpEF, the complex interplay of impaired relaxation, atrial dysfunction, stiffened myocardium, stiffening of the ventricles, and vasculature, inflammation, and endothelial dysfunction 14, 15 results in a passive backward transmission of filling pressures, causing secondary increases in pulmonary artery wedge pressure, and pulmonary artery pressure and eventually, the development of pulmonary vasculopathy. 12 Experimental studies in animal heart failure models demonstrated that treatment with sildenafil reduced the development of maladaptive cardiac hypertrophy, cardiac enlargement and fibrosis, and contractile dysfunction, and improved cell survival and diastolic function via the NO-sGC-cGMP signalling pathway. 16 -19 Targeting the NO-sGCcGMP signalling pathway has thus been proposed as a promising approach for the treatment of HFpEF with pulmonary hypertension. In our study, we could not demonstrate the beneficial effects of sildenafil in a population of HFpEF patients with mainly post-capillary pulmonary hypertension without significant pulmonary vasculopathy. An explanation could be that the beneficial effects of PDE-5 inhibitors on the myocardium in HFpEF is less than expected and that clinical and haemodynamic improvements may only be driven by possible beneficial effects on pulmonary vasculopathy if present. In recent years, several studies with other novel drugs targeting the NO-sGC-cGMP signalling pathway have been published. In a randomized, double-blind, placebo-controlled, single dose study, the novel soluble guanylate cyclase stimulator riociguat did not improve mean PAP (primary endpoint), but showed favourable haemodynamic and echocardiographic effects. 20 In a recent randomized, placebo-controlled study in 301 patients with HFpEF, the angiotensin receptor-neprilysin inhibitor LCZ696 significantly reduced NT-proBNP levels after 12 weeks of treatment, 21 and administration of LCZ696 increased circulating cGMP levels in healthy humans. 22 Further studies are needed to investigate whether this effect on NT-proBNP translates into improved clinical outcomes. In contrast to our expectations, a greater decrease in PAWP was observed in the placebo group than in the sildenafil group. As the PAWP may be associated with filling state, we evaluated concomitant medication throughout the study. We observed no differences in dose change and weight during follow-up. It is therefore unlikely that the reduction in PAWP in the placebo-treated patients may be explained by optimized care/treatment under study conditions. Interestingly, more patients in the placebo group were treated with a hydrochlorothiazide. In addition to this observation, history of hypertension was slightly higher in the placebo group. This difference may explain the higher number of patients with diuretics in the placebo group. We do not have a further valid explanation for the difference in mean change in PAWP and it should be noted that a play of chance cannot be excluded.
Concerning adverse effects, it has been reported that pulmonary selective vasodilators may lead to acute pulmonary oedema in patients with pulmonary hypertension due to HFpEF (due to selective lowering PVR, without unloading of the left ventricle). 23 As sildenafil demonstrated beneficial cardiac effects in pre-clinical studies, concomitant beneficial cardiac effects were to be expected. Overall, we did not observe significant difference in adverse effects including pulmonary oedema. However, more patients treated with sildenafil had respiratory tract infection, headache, and hypotension, which are well-known adverse effects of sildenafil. In addition to the limitations of a single centre study, the main limitation of the current study was the relatively small number of patients in each treatment group, which have limited the opportunity of analysis of subgroups of interest (high PVR vs. low PVR). We calculated the current sample size based on pilot data where we considered a reduction in mean PAP that was clinically meaningful. Indeed, we included the predefined sample size and the dropout rate was as anticipated, so our study had sufficient power to detect potential differences in PAPs after treatment with sildenafil.
In conclusion, given the lack of efficacy of sildenafil on invasively haemodynamics and exercise capacity, we cannot recommend the use of sildenafil as an adjunct in the treatment in the investigated group of HFpEF patients with associated pulmonary hypertension. In the current study, we investigated patients with predominantly isolated post-capillary pulmonary hypertension, whereas a small proportion of patients had a mild-to-moderate pre-capillary component of pulmonary hypertension also. Therefore, the role of sildenafil in selected patients with HFpEF and significant post-and pre-capillary pulmonary hypertension remains to be evaluated and should be considered for future studies.
